LL-37
Also known as: Cathelicidin
LL-37 is the only human cathelicidin antimicrobial peptide — a 37-amino-acid peptide (starting with two leucines) cleaved from the hCAP-18 precursor. It has broad-spectrum antimicrobial activity and immunomodulatory roles, but is also implicated in the pathogenesis of autoimmune and inflammatory skin diseases including psoriasis, rosacea, and lupus. Not FDA-approved; research-use only.
Who's worth your money for LL-37
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 21 scored sellers
$24.49 · 5mg · 99.0% purity
Best value
Lowest $/mg among scored sellers
$54.00 · 10mg · 99.9% purity
Most tested
8 independent COAs on file
$65.00 · 5mg · 99.8% purity
Average price
$10.42/mg
Sellers
44
45-day trend
-26.5%
35 of 44 sellers have a current price· 4 stale hidden· 10 unverified hidden
Top Merit pick
🇺🇸 Glacier Aminos99✓ verified at source · 1h ago
$4.90/mg -53% vs avg$24.49
5mg
- 🇺🇸 BioLongevity Labs96
via Disclosed Labs · 1h ago
$18.99/mg +82.2% vs avg$94.97
5mg
- 🇺🇸 Reta One Labs95
via Disclosed Labs · 1h ago
$7.20/mg -30.9% vs avg$36.00
5mg
- 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · 1h ago
$9.00/mg -13.7% vs avg$44.99
5mg
- 🇺🇸 Licensed Peptides95
✓ verified at source · 1h ago
$20.00/mg +91.8% vs avg$99.99
5mg
no purityBuy Code MERIT · 5% off - 🇺🇸 Peptide Crafters94
✓ verified at source · 1h ago
$10.00/mg -4.1% vs avg$50.00
5mg
- 🇺🇸 Certified Peptides94
✓ verified at source · 1h ago
$17.80/mg +70.8% vs avg$89.00
5mg
- 🇺🇸 Polaris Peptides90
via Disclosed Labs · 1h ago
$12.50/mg +19.9% vs avg$125
10mg
no purity - 🇺🇸 Peptide Plugs89
✓ verified at source · 1h ago
$12.00/mg +15.1% vs avg$60.00
5mg
- 🇺🇸 Soma Peptides89
✓ verified at source · 1h ago
$16.60/mg +59.2% vs avg$83.00
5mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch LL-37
Get one email when the market actually moves — no newsletter, no noise.
About LL-37
CAS
154947-66-7
Molecular formula
C205H340N60O53
Sequence
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
Typical dose range
100–400 mcg/day subcutaneous
Half-life
~4–6 hours (tissue-dependent; limited formal PK data for native LL-37)
COAs for LL-37
55 third-party tests across 19 vendors. Each card links to the full report.
For
LL-37
by CertaPeptides· batch CP-2608-LLT5
For
LL-37
by Ruo Bio· batch LL3-H-003
For
LL-37
by Glacier Aminos· batch LL5GA-01
For
LL-37
by Verified Peptides· batch LL0526030C
For
LL-37
by Peptide Plugs· batch 175-01-DK
For
LL-37
by Ion Peptide· batch L375-06092026
For
LL-37
by Ion Peptide· batch L375-06092026
For
LL-37
by Verified Peptides· batch LL05260305C
For
LL-37
by Verified Peptides· batch LL05260305C
For
LL-37
by Verified Peptides
For
LL-37
by Verified Peptides· batch LL025602005C
For
LL-37
by Real Peptides· batch Black Cap
For
LL-37
by Ion Peptide· batch LL375-03232026
For
LL-37
by Ion Peptide· batch LL375-03232026
For
LL-37
by Modern Research Peptides· batch GCEMHK0226
For
LL-37
by EZ Peptides· batch EZP-LL371002172026-01
For
LL-37
by EZ Peptides· batch EZP-LL37100217-2026-01
For
LL-37
by Peptidology· batch 1669
For
LL-37
by Ruo Bio
For
LL-37
by Simple Peptide· batch L1-05-01162026-J
For
LL-37
by Southern Aminos· batch LL050126A
For
LL-37
by Simple Peptide· batch LL10-37011220236-J
For
LL-37
by MedGe Peptides· batch LL375LT12
For
LL-37
by MedGe Peptides· batch LL375LT12
20 citations indexed for LL-37
review · 2026
Apoptosis Modulation by LL-37: From Mitochondrial Cell Death to Prosurvival Signaling
This review summarizes current knowledge on the role of human cathelicidin LL-37 in the regulation of apoptosis. LL-37 can modulate programmed cell death pathways, exerting either proapoptotic or antiapoptotic effects depending on various factors, such as cell type and peptide concentration.
Study · 2026
Coordination chemistry and antimicrobial activity of LL-37, its C-terminal fragment, and a peptidomimetic analogue
Human cathelicidin LL-37 is an antimicrobial peptide naturally present in saliva that plays an important role in host defence against bacterial and fungal pathogens. Although LL-37 is known to bind Cu(II) and Zn(II) ions, the corresponding coordination modes have remained unresolved.
review · 2026
LL-37-based oral antimicrobial therapeutics: translational challenges and future directions-a narrative review
LL-37 is an antimicrobial peptide involved in antimicrobial defence, inflammatory regulation, tissue repair, and bone regeneration in the oral cavity. Salivary and gingival crevicular fluid LL-37 levels are associated with disease activity and treatment responses.
review · 2026
LL-37: Biological Mechanisms and Emerging Therapeutic Applications in Intestinal Disease
Human cathelicidin peptide LL-37 is encoded by the CAMP gene and plays a key role in innate immunity. It maintains intestinal homeostasis through antibacterial, immunomodulation, and tissue repair functions.
Study · 2026
LL-37 and citrullinated-LL-37 enhances oxylipins: citrullination attenuates LL-37-mediated COX-2-dependent chemokine response in human bronchial epithelial cells
BACKGROUND: During airway inflammation, chemokines, oxylipins (bioactive lipids) and cationic host defence peptides (CHDP) are enhanced in the lungs. However, the interplay of these molecules in the process of airway inflammation is not fully resolved.
Study · 2026
Salivary cathelicidin LL-37 as a non-invasive biomarker for oral cancer detection
Oral squamous cell carcinoma (OSCC) is the predominant form of oral malignancy, with late-stage diagnosis contributing to poor prognosis. Oral potentially malignant disorders (OPMDs) often precede OSCC, underscoring the need for early diagnostic biomarkers.